Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
48.07
+0.43 (0.90%)
At close: Jun 26, 2026, 4:00 PM EDT
48.01
-0.06 (-0.12%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 96.82B DKK in the quarter ending March 31, 2026, with 23.99% growth. This brings the company's revenue in the last twelve months to 327.80B, up 8.13% year-over-year. In the year 2025, Novo Nordisk had annual revenue of 309.06B with 6.43% growth.
Revenue (ttm)
327.80B DKK
Revenue Growth
+8.13%
P/S Ratio
4.25
Revenue / Employee
4,716,207 DKK
Employees
69,505
Market Cap
214.87B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Bristol-Myers Squibb Company | 48.48B |
NVO News
- 18 hours ago - Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet - CNBC
- 2 days ago - Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly? - The Motley Fool
- 2 days ago - Swiss pharma at risk of US trade investigation, industry body says - Reuters
- 2 days ago - GLP-1s linked to smell and taste impairment in diabetes patients - Reuters
- 2 days ago - Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage - CNBC
- 3 days ago - An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. - The Motley Fool
- 3 days ago - Novo Nordisk (NVO) Has an Obesity-and-Diabetes Platform Bigger Than a One-Drug Hype Cycle - AlphaStreet
- 3 days ago - Lexaria Bioscience ‘s human study GLP-1-H26-7 has begun dosing - TheFly